What is kisqali?

See the DrugPatentWatch profile for kisqali

What is Kisqali used for?

Kisqali is an oral CDK4/6 inhibitor that treats HR-positive, HER2-negative advanced or metastatic breast cancer. It is given with an aromatase inhibitor as first-line therapy or with fulvestrant after prior endocrine treatment.

How does Kisqali work?

The drug blocks cyclin-dependent kinases 4 and 6, which halts cancer-cell division and slows tumor growth in hormone-receptor-positive disease.

Who makes Kisqali?

Novartis Pharmaceuticals developed and markets Kisqali.

When does Kisqali patent protection end?

Key U.S. patents covering Kisqali are scheduled to expire between 2031 and 2032, though litigation or regulatory extensions could shift these dates. Check current status on DrugPatentWatch.com.

Are Kisqali biosimilars or generics available?

No approved generic or biosimilar versions exist yet. Entry is expected only after patent expiry or a successful patent challenge.

What side effects are patients reporting?

Common side effects include neutropenia, nausea, fatigue, diarrhea, and hair thinning. Liver-function changes and QT-interval prolongation require routine monitoring.

How does Kisqali compare with Verzenio or Ibrance?

All three CDK4/6 inhibitors improve progression-free survival when added to endocrine therapy. Kisqali has shown overall-survival benefit in the MONALEESA trials, Verzenio is approved in the adjuvant setting for high-risk early breast cancer, and Ibrance has the longest market history and broadest dosing flexibility.

How much does Kisqali cost?

List price for a 28-day supply exceeds $14,000 before insurance or discounts. Novartis offers patient-assistance programs for eligible individuals.

Can Kisqali be used in early-stage breast cancer?

Kisqali is not currently approved for early-stage disease. Ongoing trials are evaluating its role in the adjuvant setting, but results are still pending.